Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04691375 · ClinicalTrials.gov registry record · Phase 1
A Study of PY314 in Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by Ikena Oncology.
- Terminated
- Registry status
- Phase 1
- Development phase
- 86
- Enrollment target
NCT04691375 is a Phase 1 study that was terminated before completion, run by Ikena Oncology. The registered enrollment target is 86 participants.
The verdict
NCT04691375, a Phase 1 study, was terminated before completion, sponsored by Ikena Oncology.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 86 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, first in human, Phase 1a/1b study of PY314 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to standard of care (including pembrolizumab, if approved for that indication).
Interventions
- DRUG PY314
- DRUG Combination Therapy: PY314 + Pembrolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2020-10-29 |
| Est. Completion | 2023-09-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04691375
The ClinicalTrials.gov registry entry for NCT04691375 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ikena Oncology, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PY314 is the first listed.
NCT04691375 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04691375 about?
NCT04691375 is a clinical study titled "A Study of PY314 in Subjects With Advanced Solid Tumors". This is an open-label, multicenter, first in human, Phase 1a/1b study of PY314 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to standard of care (including pembrolizumab, if approved for that indication).
What is the current status of trial NCT04691375?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2020-10-29. Estimated completion is 2023-09-22.
What interventions are being tested in trial NCT04691375?
The interventions under investigation include: PY314 (DRUG), Combination Therapy: PY314 + Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT04691375?
This trial is sponsored by Ikena Oncology, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.